TrialESMO open2022

Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.

E Grande et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.